The Minds Behind Mapmygenome  : Mapping the Future of Health

Anu Acharya: Education and Early Career

Anu Acharya earned her Bachelor’s degree in Physics from the Indian Institute of Technology (IIT) Kharagpur. She then pursued a Master’s degree in Physics and MIS (Management Information Systems) from the University of Illinois at Chicago. After completing her education, Anu worked in the U.S. for a few years, gaining experience in technology and leadership. (Anu Acharya)

Subash Lingareddy: Education and Early Career

Subash Lingareddy also graduated from IIT Kharagpur with a Bachelor’s degree in Physics. He holds an MS in Financial Mathematics from the University of Chicago and an MBA in Finance from the Gies College of Business at the University of Illinois, where he was a Beta Gamma Sigma honor society member.  Subash is a Chartered Financial Analyst (CFA) and has over six years of experience in roles ranging from equity analyst to financial risk manager. (Subash Lingareddy)

Previous Ventures: Ocimum Biosolutions

In 2000, Anu Acharya and Subash Lingareddy co-founded Ocimum Biosolutions, a genomics outsourcing company. Ocimum provided bioinformatics services and solutions to global clients, establishing a strong presence in the genomics industry. This venture laid the foundation for their future endeavors in personalized genomics. (Ocimum Biosolutions)

Founding of Mapmygenome

Leveraging their experience from Ocimum Biosolutions, Anu and Subash founded Mapmygenome in 2012 in Hyderabad, India. They aimed to bring personalized genomics to the Indian market, focusing on preventive healthcare. Mapmygenome offers DNA-based tests that provide insights into an individual’s genetic predispositions, helping users make informed health decisions. Under the leadership of Anu and Subash, Mapmygenome has grown to become a leader in the Indian genomics industry. The company collaborates with healthcare providers and has expanded its product offerings to cater to diverse health needs.

The Genomics Goldmine: Untangling a Billion-Dollar Market

As of 2023, the global genomics market is valued at approximately USD 32.65 billion. The market is projected to reach USD 94.86 billion by 2030, exhibiting a Compound Annual Growth Rate (CAGR) of 16.5% during the forecast period. (Grand View Research)

Key Growth Drivers

Several factors contribute to this growth:

• Advancements in Technology: Innovations in sequencing technologies have reduced costs and increased accessibility.
• Government Initiatives: Governments worldwide are investing in genomics research, further propelling market expansion.
• Rising Prevalence of Genetic Disorders: An increase in genetic disorders has heightened the demand for genomic research and diagnostics.
   

Regional Insights

North America holds a significant share of the genomics market, driven by technological advancements and substantial research funding. The Asia-Pacific region is expected to witness the fastest growth due to increasing healthcare investments and a growing focus on personalized medicine. (Mordor Intelligence)

Market Segmentation

The genomics market is segmented based on product and service, technology, application, and end-user. Key segments include:

• Products and Services: Consumables, instruments, software, and services. 
• Technology: Sequencing, polymerase chain reaction (PCR), microarray, and nucleic acid extraction.
• Application: Diagnostics, drug discovery and development, personalized medicine, and agriculture. (MarketsandMarkets)

Future Outlook

The genomics market is poised for substantial growth, driven by technological advancements, increased funding, and expanding applications in healthcare and beyond. Companies like Mapmygenome are well-positioned to capitalize on these trends, offering personalized genomic solutions to meet the evolving needs of consumers and healthcare providers.

More Than Just Genes: The Heart and Soul of Mapmygenome

Mission

Mapmygenome aims to empower individuals with genetic insights to make informed health decisions. Their mission is to provide personalized health solutions through genomics. (About Mapmygenome)

Vision

The company’s vision is to touch 100 million lives by offering genomics-based preventive healthcare. They strive to make personalized health accessible and actionable.

Problems They Solve

Mapmygenome addresses several key health challenges:

• Lack of Personalized Healthcare: Traditional healthcare often adopts a one-size-fits-all approach. Mapmygenome offers tailored health insights based on individual genetic profiles.
• Preventive Health Awareness: Many individuals seek medical attention only when ill. Mapmygenome promotes proactive health management by identifying genetic predispositions to diseases.
• Understanding Drug Responses: People react differently to medications. Mapmygenome’s pharmacogenomic tests help determine the most effective drugs and dosages for individuals.

Business Model

Mapmygenome operates on a direct-to-consumer model, offering genetic testing services online and through partner healthcare providers. Customers can order tests like Genomepatri and Medicamap via their website. The process involves:

1. Sample Collection: Customers receive a kit to collect a saliva sample at home.
2. Laboratory Analysis: The sample is analyzed in their NABL and CAP accredited labs.
3. Report Generation: A detailed report is prepared, highlighting genetic predispositions and health risks.
4. Genetic Counseling: Certified counselors help interpret the results and provide actionable health recommendations.

Additionally, Mapmygenome collaborates with hospitals, diagnostic centers, and wellness clinics to offer their services to a broader audience. They have partnered with over 40 hospitals and diagnostic centers across India.

A Genome Company: A Complete Guide to Mapmygenome’s Offerings

Genomepatri

Genomepatri is Mapmygenome’s flagship DNA-based health and wellness test. It analyzes over 100 conditions, including genetic predispositions to diseases like diabetes, heart disease, and various cancers. The test also provides insights into traits such as metabolism, fitness, and nutritional needs. Customers receive a comprehensive report and a session with a certified genetic counselor to interpret the results. (Genomepatri)

MyFitGene

MyFitGene focuses on fitness and nutrition. It examines genetic markers related to muscle strength, endurance, fat metabolism, and injury risk. The test helps individuals tailor their exercise routines and dietary plans to align with their genetic makeup. 

MyNutriGene

MyNutriGene offers personalized dietary recommendations based on genetic analysis. It assesses how an individual’s genes affect their response to carbohydrates, fats, vitamins, and minerals. The test also identifies potential food intolerances and eating behaviors, aiding in the creation of a customized nutrition plan.

MedicaMap

MedicaMap is a pharmacogenomic test that evaluates how an individual’s genetic makeup influences their response to over 100 medications. This includes drugs for cardiovascular conditions, psychiatric disorders, and pain management. The test assists healthcare providers in selecting the most effective medications and dosages, minimizing adverse drug reactions.

Genomepatri Heritage

Genomepatri Heritage is an ancestry test that explores an individual’s ethnic composition. It compares the user’s DNA with populations from over 70 global regions, with a focus on Indian ethnic subgroups. The test provides a detailed report on ancestral origins and migratory patterns.

Mapmybiome

Mapmybiome analyzes the gut microbiome to assess its impact on health, energy, and mood. The test identifies microbial species present in the gut and offers personalized dietary, probiotic, and supplement recommendations to improve gut health.

BeautyMap

BeautyMap is a DNA-based skincare solution that evaluates genetic factors affecting skin health. It provides insights into skin aging, elasticity, hydration, and sensitivity. The test offers personalized skincare and nutritional recommendations to enhance skin health.

Hereditary Cancer Panel

The Hereditary Cancer Panel is a diagnostic test that analyzes genes associated with various hereditary cancers. It helps identify genetic mutations that may increase the risk of cancers such as breast, ovarian, and colorectal cancer. The test aids in early detection and preventive measures. 

Genetic Counseling

Mapmygenome offers genetic counseling services to help individuals understand their genetic test results. Certified genetic counselors provide guidance on health risks, preventive measures, and lifestyle modifications based on genetic insights. 

Cardiomap

Cardiomap assesses genetic risk factors related to heart health and diabetes. It offers insights into predispositions to cardiac conditions and provides recommendations for preventive measures. 

Spoligo TB

Spoligo TB is a diagnostic test for tuberculosis. It utilizes PCR-based methods to detect and categorize Mycobacterium tuberculosis complexes, aiding in accurate and early diagnosis. 

Doctor-Prescribed Tests

Mapmygenome provides a range of diagnostic tests prescribed by healthcare professionals. These include tests for reproductive health, cancer, rare diseases, and organ health. The tests assist in early detection, precise diagnosis, and effective treatment planning.

How Mapmygenome Works: Science in Your Saliva

How Mapmygenome Works

Sample Collection : Mapmygenome begins by providing customers with an at-home DNA collection kit. Users collect a saliva sample using the kit and send it back to Mapmygenome’s laboratory for analysis.

DNA Extraction and Sequencing : Upon receiving the sample, the laboratory extracts DNA from the saliva. They utilize advanced sequencing technologies to analyze the genetic material. This process identifies specific genetic markers associated with various health conditions and traits.

Data Analysis and Interpretation : After sequencing, bioinformaticians analyze the genetic data. They compare the individual’s genetic markers to established databases to identify potential health risks, traits, and drug responses. This analysis helps in understanding the individual’s genetic predispositions.

Report Generation : Based on the analysis, Mapmygenome generates a comprehensive report. The report includes insights into genetic predispositions to diseases, carrier status, drug responses, and lifestyle traits. It provides actionable recommendations for health management.

Genetic Counseling : To help users understand their reports, Mapmygenome offers genetic counseling services. Certified genetic counselors explain the findings and suggest preventive measures or lifestyle modifications. 

Technology and Innovation

Mapmygenome employs cutting-edge technologies in genomics and bioinformatics. They use next-generation sequencing (NGS) for accurate and comprehensive genetic analysis. Their bioinformatics pipeline ensures precise data interpretation, translating complex genetic information into user-friendly reports.

Next-Generation Sequencing (NGS) : NGS is a high-throughput method that allows rapid sequencing of large DNA segments. Mapmygenome employs NGS to analyze multiple genes simultaneously, providing comprehensive genetic profiles. This technology enhances the accuracy and depth of genetic insights

Bioinformatics Analysis : After sequencing, Mapmygenome uses bioinformatics tools to interpret the vast amount of genetic data generated. This involves aligning sequences to reference genomes, identifying genetic variants, and assessing their potential impact on health. Advanced algorithms and databases are employed to ensure precise and meaningful interpretations.

Data Security and Privacy : Mapmygenome prioritizes data security and privacy. They implement robust measures to protect genetic information, ensuring that data is stored securely and shared only with authorized individuals. Compliance with relevant data protection regulations is maintained to safeguard user privacy.

In the Genes: Awards and Impact Making Headlines

Mapmygenome has significantly influenced India’s genomics and personalized healthcare sectors. The company has collaborated with over 40 hospitals and diagnostic centers across India. In 2023, Mapmygenome received accreditation from the National Accreditation Board for Testing and Calibration Laboratories (NABL). (Medgate Today)

2021: Startup of the Year Award

In August 2021, the Government of India honored Mapmygenome with the Startup of the Year award in the healthtech category. This accolade was part of the MeitY-Nasscom Startup Women Entrepreneur Awards 2020-21, recognizing the company’s innovation and impact in the health technology. (Telangana Today)

2020: Contribution to COVID-19 Efforts

During the COVID-19 pandemic, Mapmygenome expanded its services to include COVID-19 testing. The company played a crucial role in India’s response to the pandemic. (Inc42)

2016: International Recognition

In 2016, Mapmygenome was selected as a finalist for the Wall Street Journal’s Annual Startup Showcase for their innovative approach to personalized healthcare and its potential for global impact. (YouTube)

Team Genome: Building Bonds for a Healthier Tomorrow

Collaboration with Humanity Inc.

In June 2024, Mapmygenome partnered with Humanity Inc., a U.S.-based health and longevity data analysis company to combine advanced genomics with data analytics to deliver holistic health solutions through the Humanity AI Health Coach App. The partnership creates personalized health plans and facilitates collaborative research in genomics and data analytics. (Humanity Inc)

Alliance with iMeUsWe

In May 2024, Mapmygenome joined forces with iMeUsWe to offer DNA testing services to provide individuals with comprehensive health insights, including genetic predispositions to various health conditions. The service also includes complimentary genetic counseling sessions to help users develop personalized action plans. (Voice of Healthcare)

Partnership with Food Darzee

In December 2022, Mapmygenome collaborated with Food Darzee, a Mumbai-based food and nutrition startup to help people achieve their fitness and nutrition goals by providing personalized health services that combine genomic testing and nutrition. (Darzee)

Collaboration with DNAtix

In August 2018, Mapmygenome partnered with DNAtix, a blockchain genetics company to advance personalized preventive medicine by providing anonymous and encrypted genome sequencing and genetic services. The collaboration allows users to explore their genetic makeup in new ways, with security and anonymity as top priorities. (DNAtix)

Funding the Future: How Mapmygenome Scales Up

Mapmygenome, founded in 2012, has raised a total of $1.69 million over five funding rounds. The company has attracted investments from 26 investors, including notable names like Singapore Angel Network and Currae Healthtech Fund. (Tracxn)

Seed Round: February 25, 2015

Mapmygenome secured $1.1 million in its initial seed funding. The round was led by Singapore Angel Network and CMS, with participation from angel investors including Mayur M. Desai, Hemant Hansraj, and Rajan Anandan. At this stage, the company’s valuation stood at $5.9 million, and it reported a revenue of $227,000.

Seed Round: September 25, 2017

In a subsequent seed round, Mapmygenome raised $116,000. This round saw investments from Singapore Angel Network, Currae Healthtech Fund, CMS, and angel investors such as Rajan Anandan and Apoorva Patni. The company’s valuation increased to $5.7 million, with a reported revenue of $587,000.

Angel Round: March 21, 2018

The company raised $199,000 in an angel funding round, with notable investment from Ratan N. Tata. At this point, Mapmygenome’s valuation was $9.4 million, and it reported a revenue of $644,000.

Angel Round: December 9, 2019

Mapmygenome secured $271,000 in another angel funding round. Investors included Arjun Malhotra, M. Vidyasagar, and R. Gopala Krishnan. The company’s valuation reached $8.9 million, with a reported revenue of $1.1 million.

Angel Round: November 2, 2020

In its latest disclosed funding round, Mapmygenome raised an undisclosed amount from angel investor Anula Kusum Jayasuriya. The company reported a revenue of $2.6 million for this period.

Revenue Insights

As of March 31, 2023, Mapmygenome reported annual revenue of approximately ₹26.8 crore (around $3.34 million). This reflects the company’s growth and increasing market presence in the genomics sector.

The Final Strand: Unraveling Health with Mapmygenome

Mapmygenome is transforming healthcare by making genetic insights accessible to everyone. Through at-home DNA testing, Mapmygenome helps individuals understand their unique genetic makeup. They offer a wide range of services, including Genomepatri for health and wellness insights, Medicamap for personalized medication recommendations, and other tests for fitness, nutrition, and ancestry. 

The company’s goal is to empower people to take control of their health by identifying genetic predispositions early on. By combining advanced technology and personalized counseling, Mapmygenome is pioneering a new era of preventive healthcare in India and beyond.

Mapmygenome’s journey shows how an idea can change an entire industry. If you have ideas that could make a difference, start working on them. The future of health, technology, or any industry depends on the bold ideas of today. For those interested in learning about other innovative companies, check out the articles on Venture Kites. We explore inspiring ventures across industries, offering insights into what makes or breaks them.